

Amendments to the Claims

The listing of claims below is intended to replace all prior listings of the claims:

1-9. (Cancelled)

10. (Currently Amended) A method for treating or preventing ~~a condition related to synthesis of an ECM protein, the method including modulating the expression and/or activity of a CDA~~ cell division autoantigen-1 (CDA1) modulated renal fibrosis, the fibrosis resulting from diabetes, the method comprising:

administering to a subject in need thereof a therapeutically or prophylactically effective amount of an AT1 receptor antagonist, wherein the administration of the AT1 receptor antagonist reduces the expression or activity of CDA1 in a kidney cell of the subject, the administration leading to a decrease in the expression of an extracellular matrix protein in a kidney of the subject, thereby treating or preventing the CDA1 modulated renal fibrosis resulting from diabetes.

11-32. (Cancelled)

33. (New) The method according to claim 10, wherein the AT1 receptor antagonist is valsartan.

34. (New) The method according to claim 10, wherein the subject is a mammal.

35. (New) The method according to claim 10, wherein said administering is carried out to treat CDA1 modulated renal fibrosis resulting from diabetes.